S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Enanta Pharmaceuticals (ENTA) Competitors

$13.23
-0.77 (-5.50%)
(As of 04/18/2024 ET)

ENTA vs. AKBA, ZVRA, GNFT, VXRT, SGMT, KPTI, KNTE, SPRO, ARCT, and PRTA

Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Akebia Therapeutics (AKBA), Zevra Therapeutics (ZVRA), Genfit (GNFT), Vaxart (VXRT), Sagimet Biosciences (SGMT), Karyopharm Therapeutics (KPTI), Kinnate Biopharma (KNTE), Spero Therapeutics (SPRO), Arcturus Therapeutics (ARCT), and Prothena (PRTA). These companies are all part of the "medical" sector.

Enanta Pharmaceuticals vs.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.

In the previous week, Enanta Pharmaceuticals and Enanta Pharmaceuticals both had 2 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.61 beat Akebia Therapeutics' score of 0.76 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enanta Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Akebia Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Akebia Therapeutics has a net margin of -26.32% compared to Enanta Pharmaceuticals' net margin of -187.77%. Akebia Therapeutics' return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Enanta Pharmaceuticals-187.77% -60.38% -32.29%
Akebia Therapeutics -26.32%N/A -20.36%

Enanta Pharmaceuticals has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 3.8% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Akebia Therapeutics has higher revenue and earnings than Enanta Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$79.20M3.53-$133.82M-$6.56-2.02
Akebia Therapeutics$194.62M1.50-$51.92M-$0.28-4.96

Akebia Therapeutics received 101 more outperform votes than Enanta Pharmaceuticals when rated by MarketBeat users. Likewise, 64.01% of users gave Akebia Therapeutics an outperform vote while only 56.41% of users gave Enanta Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Enanta PharmaceuticalsOutperform Votes
308
56.41%
Underperform Votes
238
43.59%
Akebia TherapeuticsOutperform Votes
409
64.01%
Underperform Votes
230
35.99%

Enanta Pharmaceuticals presently has a consensus target price of $19.33, indicating a potential upside of 46.13%. Akebia Therapeutics has a consensus target price of $5.00, indicating a potential upside of 259.71%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Enanta Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enanta Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Akebia Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Akebia Therapeutics beats Enanta Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

Get Enanta Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENTA vs. The Competition

MetricEnanta PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$279.95M$6.40B$4.75B$7.44B
Dividend YieldN/A2.97%2.98%4.00%
P/E Ratio-2.0212.85231.0517.68
Price / Sales3.53330.462,318.5584.57
Price / CashN/A20.9447.1435.12
Price / Book1.295.484.584.19
Net Income-$133.82M$145.97M$104.25M$214.08M
7 Day Performance-21.01%-7.89%-5.39%-4.90%
1 Month Performance-2.07%-7.58%-4.86%-3.50%
1 Year Performance-64.60%-3.43%8.42%3.81%

Enanta Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKBA
Akebia Therapeutics
3.7766 of 5 stars
$1.54
+0.7%
$5.00
+224.7%
+113.8%$322.43M$194.62M-5.50167
ZVRA
Zevra Therapeutics
1.2537 of 5 stars
$4.73
-4.3%
$19.50
+312.3%
-25.5%$205.42M$27.46M-3.6732Analyst Revision
GNFT
Genfit
0.7946 of 5 stars
$3.73
+7.8%
$11.00
+194.9%
-10.8%$185.87M$41.31M0.00154Gap Down
VXRT
Vaxart
0.9323 of 5 stars
$1.04
-3.7%
$3.00
+188.5%
+25.0%$180.81M$7.38M-1.79109News Coverage
SGMT
Sagimet Biosciences
2.9281 of 5 stars
$5.31
-1.3%
$41.50
+681.5%
N/A$169.44M$2M0.008Gap Down
KPTI
Karyopharm Therapeutics
3.2265 of 5 stars
$1.34
-0.7%
$5.67
+322.9%
-69.9%$154.19M$146.03M-1.07325Gap Up
KNTE
Kinnate Biopharma
4.3914 of 5 stars
$2.65
-0.4%
$11.72
+342.2%
-49.8%$125.13MN/A-0.9584Positive News
High Trading Volume
SPRO
Spero Therapeutics
4.367 of 5 stars
$1.69
+0.6%
$7.00
+314.2%
-14.8%$91.04M$103.78M4.0246
ARCT
Arcturus Therapeutics
1.8501 of 5 stars
$31.66
+2.4%
$61.33
+93.7%
0.0%$832.48M$157.75M-30.44180
PRTA
Prothena
2.8342 of 5 stars
$23.54
-0.6%
$69.63
+195.8%
-60.6%$1.27B$91.37M-8.41173Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:ENTA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners